Introduction to lung cancer treatment
Oncological data for 2024 show that lung cancer and mortality rates are among the highest.
The factors contributing to lung cancer are: 1. smoking, including active and passive smoking, such as industrial smoke, kitchen smoke, etc.; 2. environmental pollution, such as haze, car tail gas, etc.; 3. Family genetic factors; 4. increased pace of life, increased stress, etc.
The clinical manifestations of lung cancer are: 1. irritating cough with no apparent incentivation, aggravated with coughing, suffocation, short breath, chest ache, blood breaks, etc., depending on the early and lateness of the condition; 2. breeching with pressure of the upper cavity can lead to increased ingestion or even failure to eat; 4. pain and functional impairment of the corresponding transferal part may occur in the event of a remote transfer, e.g., pain in the back of the upper lymphobar, an abnormal feeling in the nerve, or even a reduction in muscle strength, or a failure to speak; pressure on the tremor tube can cause respiratory difficulties; constriction can cause increased ingestion, or even failure to eat; pain and functional impairment in the corresponding transferal part may occur in the event of a transfer, e.g., pain in the back of the upper lymphatic lynch, an abnormal and even a reduction in the strength of the body, a failure to rejugate, and a reduction in the pressure of the back of the brain.
Pulmonary cancer is divided into: 1. central and peripheral; 2. small cell lung cancer and non-small cell lung cancer, non-small cell lung cancer, which also includes cystal cancer, gland cancer, large cell cancer, gland cell cancer, carmatoma cancer, etc.
Pulmonary cancer is phased in four periods:
Principles for the treatment of lung cancer: Different treatments are used depending on the pathology of lung cancer and its stratification. This is about non-small cell lung cancer. Phase I: The combination of surgical ectoplasmic diseases or surgical taboos may be considered for the use of stereodirective radiotherapy or radiofrequency digestion treatment; Phase II: the selection of new assisted chemotherapy or new assisted treatment after surgical treatment may be based on the condition, after which the assisted target or immunotherapy may be performed according to the pathology; if the surgery is not possible for a number of reasons, it is recommended for simultaneous leaching treatment, followed by immuno-maintenance treatment or target treatment; Phase III: this part of the patient is more complex and is recommended for multidisciplinary treatment, with surgical removal, potential surgical removal, with the possibility of surgical removal, with the possibility of surgical removal of more types, and in general, with the possibility of a new assisted treatment after surgery; if the surgery is not possible, the person is able to perform a synchronized treatment, followed by assisted immunotherapy or target treatment; Phase IV: whole body treatment, with chemical, target, immunotherapy, and medium medicine, with nutritional support, treatment, etc.
Pulmonary cancer follow-up: if the patient is stable after the first stage of treatment, a comprehensive review is completed and the condition is fully mitigated. Follow-up requires regular outpatient review to monitor changes in the condition and to detect a recurrence of the disease in a timely manner so that treatment can be provided. The first three months of treatment are normally reviewed once, every six months after two years and every five years thereafter!
Finally, it is hoped that the vast majority of patients will receive a standard treatment, overcome the disease, recover soon and be reintegrated into society and the family!
Lung cancer
